Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4-Reference-Cited by-同舟云学术

Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4

Published:2018-07-13 Issue:15 Volume:61 Page:6574-6591
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lamaa Diana¹,Lin Hsin-Ping¹,Zig Lena²,Bauvais Cyril³,Bollot Guillaume³,Bignon Jérôme⁴,Levaique Helene⁴,Pamlard Olivier⁴,Dubois Joelle⁴,Ouaissi Mehdi⁵,Souce Martin⁶,Kasselouri Athena⁶,Saller François⁷,Borgel Delphine⁷,Jayat-Vignoles Chantal⁸,Al-Mouhammad Hazar⁸,Feuillard Jean⁸⁹,Benihoud Karim²,Alami Mouad¹,Hamze Abdallah¹^ORCID

Affiliation:

1. BioCIS, Univ. Paris-Sud, CNRS, équipe labellisée Ligue Contre le Cancer, Université Paris-Saclay, 92290 Châtenay-Malabry, France

2. Vectorologie et thérapeutiques anticancéreuses, UMR 8203 CNRS, Univ. Paris-Sud, Institut Gustave Roussy, Université Paris-Saclay, Villejuif 94805, France

3. SYNSIGHT, 86 rue de Paris, Orsay 91400, France

4. CIBI platform, Institut de Chimie des Substances Naturelles, UPR 2301, CNRS avenue de la terrasse, F-91198 Gif sur Yvette, France

5. CHRU Hôpital de Tours Trousseau, Service de chirurgie digestive, oncologique, endocrinienne et de transplantation hépatique, avenue de la République, 37170 Chambray-lès-Tours, France

6. Lip(Sys)2, Chimie Analytique Pharmaceutique, Univ Paris-Sud, Université Paris-Saclay, F-92290 Châtenay-Malabry, France

7. INSERM, UMR-S1176, University Paris-Saclay, F-94276 Le Kremlin-Bicêtre, France

8. Univ Limoges, Faculté de Médecine, CNRS UMR 7276, Laboratoire CRIBL, F-87025 Limoges, France

9. CHU Limoges, Hôpital Dupuytren, Service d’hématologie, F-87025 Limoges, France

Funder

Agence Nationale de la Recherche

Ligue Contre le Cancer

Centre National de la Recherche Scientifique

Universit? Paris-Sud

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00050

Reference58 articles.

1. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm

2. Polypharmacology: Challenges and Opportunities in Drug Discovery

3. Anticancer Hybrids

4. Hybrid Molecules with a Dual Mode of Action: Dream or Reality?

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of class I HDAC modulators: Inhibitors and degraders;European Journal of Medicinal Chemistry;2024-10

2. Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects;Journal of Medicinal Chemistry;2024-07-20

3. The Potential Strategies for Overcoming Multidrug Resistance and Reducing Side Effects of Monomer Tubulin Inhibitors for Cancer Therapy;Current Medicinal Chemistry;2024-04

4. Design and biological evaluation of dual tubulin/HDAC inhibitors based on millepachine for treatment of prostate cancer;European Journal of Medicinal Chemistry;2024-03

5. Design, synthesis and tubulin polymerization inhibition activity of newly synthesized hydrazone-linked to combretastatin analogues as potential anticancer agents;Journal of Molecular Structure;2023-11